CCNA Team 2: Inflammation and Nerve Growth Factors

“The early, asymptomatic stage of Alzheimer’s disease (referred to as “pre-clinical AD”) should be responsive to disease modifying therapy. Our objective is to explore these early events in order to identify targets for AD diagnosis, prevention, and treatment. Given our significant preliminary findings, we are focusing our studies on inflammation and trophic factor metabolism, as the AD progresses from pre-clinical to clinical presentation.”